Surgical treatment of 61 consecutive patients with maxillary stage 3 medication–related osteonecrosis of the jaws using a pedicled buccal fat pad

Andersen, Sanne Werner Moeller; Mogensen, Ditte Gertz; Schioedt, Morten; Kofod, Thomas

doi:10.1007/s10006-022-01061-2

Cited by 3 publications

(2 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The procedure is planned from a 3D cone beam or multislice CT scan. Surgical treatment is performed in combination with antibiotic therapy (amoxicillin with clavulanic acid, 3 g/day, a minimum of one day before and 6-9 days after surgery) [46]. An incision is made that extends from the perforation of the osteonecrosis in both mesial and distal directions on the alveolar ridge.…”

Section: Medication-related Osteonecrosis Of the Jaw And Multiple Mye...mentioning

confidence: 99%

Novel Developments in the Treatment of Multiple Myeloma-Associated Bone Disease

Johansen,

Levring,

Stokbro

et al. 2023

Cancers

View full text Add to dashboard Cite

Osteolytic bone disease is present in about 80% of patients with multiple myeloma at the time of diagnosis. Managing bone disease in patients with multiple myeloma is a challenge and requires a multi-faceted treatment approach with medication, surgery, and radiation. The established treatments with intravenous or subcutaneous antiresorptives can cause debilitating adverse events for patients, mainly osteonecrosis of the jaw, which, traditionally, has been difficult to manage. Now, oral surgery is recommended and proven successful in 60–85% of patients. Patients with spinal involvement may benefit from surgery in the form of vertebroplasty and kyphoplasty for pain relief, improved mobility, and reestablished sagittal balance, as well as the restoration of vertebral height. These procedures are considered safe, but the full therapeutic impact needs to be investigated further. Ixazomib, the first oral proteasome inhibitor, increases osteoblast differentiation, and recently published preliminary results in patients treated with Ixazomib maintenance have promisingly shown increased trabecular volume caused by prolonged bone formation activity. Other novel potential treatment strategies are discussed as well.

show abstract

Section: Medication-related Osteonecrosis Of the Jaw And Multiple Mye...mentioning

confidence: 99%

Novel Developments in the Treatment of Multiple Myeloma-Associated Bone Disease

Johansen,

Levring,

Stokbro

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…Preventive measures and guidelines for patient management are continually refined based on emerging evidence [1]. Clinical approaches to treat MRONJ involve a multidisciplinary strategy, including discontinuation or modification of the causative medication (if possible), antimicrobial therapy to manage infections, and surgical interventions such as debridement or resection of necrotic bone [37][38][39]. Complex surgical approaches are frequently required for more severe cases [40].…”

Section: Introductionmentioning

confidence: 99%

Clinical Performance of Implant-Supported Prostheses in the Rehabilitation of Patients Previously Treated for Medication-Related Osteonecrosis of the Jaws (MRONJ): A Systematic Review

Anitua,

Alkhraisat,

Eguia

2024

Cureus

View full text Add to dashboard Cite

There is a lack of consensus on managing resultant bone and soft tissue defects or on restoring oral function and aesthetics following medication-related osteonecrosis of the jaws (MRONJ) lesion healing. This clinical challenge presents a dilemma for practitioners. Removable prostheses pose a recurrence risk if poorly fitted and may inadequately restore function or aesthetics in cases of significant bone defect. Dental implant-supported prostheses could enhance function and quality of life, though their risks and indications are not well-defined. This systematic review examines the clinical outcomes and complications associated with implant-supported rehabilitations post-MRONJ surgery. This study was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement recommendations and it was pre-registered in the Prospective Register of Systematic Reviews (PROSPERO) (CRD42023492539).

show abstract